Skip to main content
Medical information Clinical review pending

Genetic Testing

SCARB2 Gene Epilepsy Progressive Myoclonic Type 4 with or without Renal Failure Genetic Test

Genetic test to identify mutations in the SCARB2 gene associated with Progressive Myoclonic Epilepsy Type 4, which may include renal failure. Helps in diagnosis and understanding potential causes of neurological symptoms.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
Generally, no special preparation is required for a blood draw. However, confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the SCARB2 Gene Epilepsy Progressive Myoclonic Type 4 with or without Renal Failure Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected Progressive Myoclonic Epilepsy Type 4
  • ✓Neurological symptoms consistent with the condition
  • ✓Family history of Progressive Myoclonic Epilepsy Type 4
  • ✓Presence of unexplained renal failure alongside neurological symptoms
  • ✓Genetic counseling for families with related conditions
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the SCARB2 gene linked to Progressive Myoclonic Epilepsy Type 4, potentially aiding in diagnosis, understanding disease mechanisms, and informing treatment strategies.
The SCARB2 Gene Epilepsy Progressive Myoclonic Type 4 with or without Renal Failure NGS Genetic DNA Test is a diagnostic tool used to detect genetic changes in the SCARB2 gene. These changes are linked to a specific type of progressive myoclonic epilepsy, sometimes accompanied by kidney problems (renal failure). This test can provide valuable information for individuals experiencing symptoms related to this condition.

This test analyzes your DNA to look for mutations within the SCARB2 gene. Identifying such mutations can help confirm a diagnosis, understand the underlying cause of symptoms, and guide medical management. It is particularly relevant for individuals with neurological symptoms suggestive of this condition or a family history of related disorders.

Understanding the genetic basis of the condition can also inform family planning and genetic counseling discussions. Discussing the results with a healthcare provider is crucial to interpret their meaning and determine appropriate next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationGenerally, no special preparation is required for a blood draw. However, confirm with the laboratory for any specific instructions.
SampleBlood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) of the SCARB2 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically looks for mutations in the SCARB2 gene. It does not detect mutations in other genes that might cause similar symptoms. A negative result does not completely rule out a genetic cause for the condition. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This is a rare genetic disorder characterized by progressive neurological symptoms, including myoclonus (jerky muscle movements), seizures, and cognitive decline. It can sometimes be associated with kidney problems.
Individuals experiencing symptoms suggestive of Progressive Myoclonic Epilepsy Type 4, or those with a family history of the condition, may be recommended for this test by their doctor.
The test involves analyzing a sample of your DNA, typically obtained from a blood sample, to look for specific changes (mutations) in the SCARB2 gene.
Results are interpreted by a qualified specialist and should be discussed with your healthcare provider to understand their implications for your health and management.
While identifying the genetic mutation confirms the diagnosis, this test may not always predict the exact severity or progression of the condition. Clinical evaluation remains essential.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp